STA
BMY icon

Summit Trail Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Summit Trail Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12M Buy
71,425
+111
+0.2% +$6.37K 0.05% 236
2026
Q1 		$4.33M Buy
71,314
+16,548
+30% +$965K 0.06% 189
2025
Q4 		$2.95M Sell
54,766
-6,469
-11% -$311K 0.05% 243
2025
Q3 		$2.76M Sell
61,235
-322
-0.5% -$15K 0.04% 282
2025
Q2 		$2.85M Buy
+61,557
New +$3.02M 0.05% 196
2024
Q4 		– Sell
-49,473
Closed -$2.56M – 451
2024
Q3 		$2.56M Buy
49,473
+894
+2% +$41.9K 0.06% 136
2024
Q2 		$2.02M Buy
48,579
+32,236
+197% +$1.44M 0.05% 144
2024
Q1 		$886K Buy
16,343
+4,717
+41% +$240K 0.02% 234
2023
Q4 		$597K Sell
11,626
-1,765
-13% -$92.6K 0.02% 251
2023
Q3 		$777K Sell
13,391
-2,389
-15% -$146K 0.03% 202
2023
Q2 		$1.01M Buy
15,780
+5,064
+47% +$340K 0.04% 169
2023
Q1 		$743K Buy
10,716
+5,136
+92% +$362K 0.03% 165
2022
Q4 		$401K Sell
5,580
-583
-9% -$44K 0.02% 218
2022
Q3 		$438K Buy
6,163
+1,098
+22% +$79.6K 0.02% 202
2022
Q2 		$393K Buy
5,065
+1,842
+57% +$140K 0.02% 222
2022
Q1 		$237K Buy
+3,223
New +$216K 0.02% 280
2020
Q4 		– Sell
-4,086
Closed -$256K – 203
2020
Q3 		$256K Buy
+4,086
New +$246K 0.05% 175
2018
Q2 		– Sell
-7,710
Closed -$279K – 509
2018
Q1 		$279K Sell
7,710
-245
-3% -$15.8K 0.05% 294
2017
Q4 		$503K Buy
+7,955
New +$498K 0.06% 228

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Summit Trail Advisors's BMY Position: Q2 2026 in Review

Summit Trail Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.16% in Q2 2026, buying an estimated $6.37K and bringing the position to 71,425 shares worth $4.12M. The position accounts for 0.05% of the portfolio, ranked #236.

Summit Trail Advisors first reported a position in BMY in Q4 2017 and has held it in 19 quarters since. The position peaked at $4.33M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Summit Trail Advisors held 71,425 shares of Bristol-Myers Squibb worth $4.12M as of Q2 2026.
  • Summit Trail Advisors bought 111 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.37K.
  • Bristol-Myers Squibb made up 0.05% of Summit Trail Advisors's portfolio in Q2 2026, its #236 holding.
  • Summit Trail Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 19 quarters since.
  • Summit Trail Advisors's Bristol-Myers Squibb position peaked at $4.33M in Q1 2026.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.